Acute Kidney Injury in Patients Undergoing Chronic Hepatitis C Virus Treatment With Ledipasvir/Sofosbuvir

Ledipasvir‐sofosbuvir, a once‐a‐day, oral combination pill, was approved in 2014 for the treatment of chronic hepatitis C infection. Initial trials did not comment on nephrotoxicity; however, recent data suggest a risk of acute kidney injury (AKI) with the use of the medication. We assessed the rate...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Patrick R., Sadiq, Omar, Weick, Alexander, Lenhart, Adrienne, Elbatta, Mohammad, Fernandez, Christopher, Kutait, Anas, Pompa, Robert, Jafri, Syed‐Mohammed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167069/
https://www.ncbi.nlm.nih.gov/pubmed/30288472
http://dx.doi.org/10.1002/hep4.1243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167069/
https://www.ncbi.nlm.nih.gov/pubmed/30288472
http://dx.doi.org/10.1002/hep4.1243

Ejemplares similares